Ocrelizumab associates with reduced cerebrospinal fluid B and CD20^dim CD4⁺ T cells in primary progressive multiple sclerosis.

ABSTRACT: The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B-cell marker; however, subpopulations of CD4⁺ and CD8⁺ T cells in peripheral blood and cerebrospinal fluid also express low levels of CD20 (CD20^dim). Therefore, direct targeting and depletion of these CD20^dim T-cell subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20⁺ B-cell and CD20^dim T-cell distributions between peripheral blood and cerebrospinal fluid of ocrelizumab-treated or ocrelizumab-untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depleti

SUBMITTER: van Puijfelik F 

PROVIDER: S-EPMC10881107 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature